keyword
MENU ▼
Read by QxMD icon Read
search

statin in acute coronary syndrome

keyword
https://www.readbyqxmd.com/read/28325524/current-status-of-lipid-management-in-acute-coronary-syndrome
#1
REVIEW
Koichiro Fujisue, Kenichi Tsujita
The development of coronary revascularization has dramatically improved early cardiovascular outcomes in patients with acute coronary syndrome (ACS). However, patients who have experienced myocardial infarction (MI) are at high risk of recurrence of cardiovascular events compared with those who are healthy or have stable coronary artery disease. Acute coronary events induce further inflammatory responses and plaque vulnerability in either a coronary culprit or whole vessels. The majority of data have supported the importance of coronary risk management to prevent secondary events...
March 18, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28321012/impact-of-lipoprotein-a-on-long-term-outcomes-in-patients-with-coronary-artery-disease-treated-with-statin-after-a-first-percutaneous-coronary-intervention
#2
Satoru Suwa, Manabu Ogita, Katsumi Miyauchi, Taketo Sonoda, Hirokazu Konishi, Shuta Tsuboi, Hideki Wada, Ryo Naito, Tomotaka Dohi, Takatoshi Kasai, Shinya Okazaki, Kikuo Isoda, Hiroyuki Daida
AIMS: Cardiovascular risk persists despite intensive lipid lowering therapy using statins. Serum levels of lipoprotein (a) [Lp(a)] can be a residual cardiovascular risk for adverse events. Aim of the present study was to evaluate the impact of Lp(a) on long-term clinical outcomes in patients treated with statin after percutaneous coronary intervention. METHODS: We prospectively enrolled 3507 consecutive CAD patients who underwent a first percutaneous coronary intervention (PCI) between 1997 and 2011 at our institution...
March 17, 2017: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/28294854/-registry-of-acute-coronary-syndromes-record-3-characteristics-of-patients-and-treatment-during-initial-hospitalization
#3
A D Erlikh, N A Gratsiansky On Behalf Of Record-Participants
Acute Coronary Syndrome (ACS) Registries RECORD 1-2 (2007-2001) gave valuable information on management of ACS patients in Russia. RECORD-3 was carried out in March-April, 2015. Here we present characteristics of included patients (pts) and data on their treatment during initial hospitalization. MATERIAL AND METHODS: RECORD-3 recruited pts with suspected ACS consecutively hospitalized in participating hospitals (n=47, 55% "invasive") during 1 month. RESULTS: Number of included pts was 2370 (39% women, mean age 64...
April 2016: Kardiologiia
https://www.readbyqxmd.com/read/28291866/long-term-safety-and-efficacy-of-achieving-very-low-levels-of-low-density-lipoprotein-cholesterol-a-prespecified-analysis-of-the-improve-it-trial
#4
Robert P Giugliano, Stephen D Wiviott, Michael A Blazing, Gaetano M De Ferrari, Jeong-Gun Park, Sabina A Murphy, Jennifer A White, Andrew M Tershakovec, Christopher P Cannon, Eugene Braunwald
Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. The safety of very low LDL-C levels over the long-term is unknown. Objective: To assess the safety and clinical efficacy of achieving a very low (<30 mg/dL) level of LDL-C at 1 month using data from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial...
March 14, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28291622/a-randomized-controlled-comparison-of-different-intensive-lipid-lowering-therapies-in-chinese-patients-with-non-st-elevation-acute-coronary-syndrome-nste-acs-ezetimibe-and-rosuvastatin-versus-high-dose-rosuvastatin
#5
Dan Ran, Hui-Juan Nie, Yu-Lin Gao, Song-Bai Deng, Jian-Lin Du, Ya-Jie Liu, Xiao-Dong Jing, Qiang She
BACKGROUND: Statin combined with ezetimibe demonstrates significant benefit in lowering low density lipid cholesterol (LDL-C) and cardiovascular events abroad, but whether intermediate intensity statins combined with ezetimibe is superior to high-intensity statin monotherapy in Chinese people is unknown. METHODS: A total of 125 patients were randomly assigned to a intermediate intensity rosuvastatin group (rosuvastatin 10mg/d, n=42), high-dose rosuvastatin group (rosuvastatin 20mg/d, n=41) or combination therapy group (ezetimibe 10mg/d and rosuvastatin 10mg/d, n=42) with a 12-week follow-up...
February 23, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28281026/neoatherosclerosis-assessed-with-optical-coherence-tomography-in-restenotic-bare-metal-and-first-and-second-generation-drug-eluting-stents
#6
Lei Song, Gary S Mintz, Dong Yin, Myong Hwa Yamamoto, Chee Yang Chin, Mitsuaki Matsumura, Khady Fall, Ajay J Kirtane, Manish A Parikh, Jeffrey W Moses, Ziad A Ali, Richard A Shlofmitz, Akiko Maehara
Although reported in bare metal stents (BMS) and first-generation drug-eluting stents (DES), little is known about neoatherosclerosis in second-generation DES. We used optical coherence tomography to evaluate neoatherosclerosis among different stent generations. Overall, 274 in-stent restenosis (ISR) lesions (duration from implantation 56.9 ± 47.2 months) in 274 patients were assessed for the presence of neoatherosclerosis. Neoatherosclerosis was identified in 38.7% of lesions (106/274): 23.0% second-generation DES (38/165), 65...
March 9, 2017: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/28279371/carotid-plaque-lipid-content-and-fibrous-cap-status-predict-systemic-cv-outcomes-the-mri-substudy-in-aim-high
#7
Jie Sun, Xue-Qiao Zhao, Niranjan Balu, Moni B Neradilek, Daniel A Isquith, Kiyofumi Yamada, Gádor Cantón, John R Crouse, Todd J Anderson, John Huston, Kevin O'Brien, Daniel S Hippe, Nayak L Polissar, Chun Yuan, Thomas S Hatsukami
OBJECTIVES: The aim of this study was to investigate whether and what carotid plaque characteristics predict systemic cardiovascular outcomes in patients with clinically established atherosclerotic disease. BACKGROUND: Advancements in atherosclerosis imaging have allowed assessment of various plaque characteristics, some of which are more directly linked to the pathogenesis of acute cardiovascular events compared to plaque burden. METHODS: As part of the event-driven clinical trial AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes), subjects with clinically established atherosclerotic disease underwent multicontrast carotid magnetic resonance imaging (MRI) to detect plaque tissue composition and high-risk features...
March 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28266936/statins-haemostatic-factors-and-thrombotic-risk
#8
Vanessa Bianconi, Amirhossein Sahebkar, Maciej Banach, Matteo Pirro
PURPOSE OF REVIEW: Statins reduce cholesterol synthesis and promote low-density lipoprotein clearance from circulation. Beyond their cholesterol-lowering action, statins may interfere with haemostasis. This review aims to provide an update on the impact of statin treatment on markers of haemostasis and platelet function and on thrombosis-related outcomes. RECENT FINDINGS: Different coagulation factors are modulated by statins, leading to inhibition of coagulation and increased fibrinolysis...
March 6, 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/28249992/effect-of-cost-sharing-on-adherence-to-evidence-based-medications-in-patients-with-acute-coronary-syndrome
#9
Beatriz González López-Valcárcel, Julián Librero, Aníbal García-Sempere, Luz María Peña, Sofía Bauer, Jaume Puig-Junoy, Juan Oliva, Salvador Peiró, Gabriel Sanfélix-Gimeno
OBJECTIVES: Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia. METHODS: Population-based retrospective cohort of 10 563 patients discharged alive after an ACS in 2009-2011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%...
March 1, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28242176/2017-taiwan-lipid-guidelines-for-high-risk-patients
#10
REVIEW
Yi-Heng Li, Kwo-Chang Ueng, Jiann-Shing Jeng, Min-Ji Charng, Tsung-Hsien Lin, Kuo-Liong Chien, Chih-Yuan Wang, Ting-Hsing Chao, Ping-Yen Liu, Cheng-Huang Su, Shih-Chieh Chien, Chia-Wei Liou, Sung-Chun Tang, Chun-Chuan Lee, Tse-Ya Yu, Jaw-Wen Chen, Chau-Chung Wu, Hung-I Yeh
In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD). Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and familial hypercholesterolemia (FH), lipid control is also necessary in these patients...
February 24, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28209375/suboptimal-achievement-of-low-density-lipoprotein-cholesterol-targets-in-french-patients-with-coronary-heart-disease-contemporary-data-from-the-dysis-ii-acs-chd-study
#11
MULTICENTER STUDY
Jean Ferrières, Maja Velkovski Rouyer, Dominik Lautsch, Veronica Ashton, Baishali M Ambegaonkar, Philippe Brudi, Anselm K Gitt
BACKGROUND: European guidelines recommend a low-density lipoprotein cholesterol (LDL-C) target of<1.8mmol/L (70mg/dL), and/or a≥50% reduction when the target level cannot be reached, for patients at very high cardiovascular risk, and high-potency lipid-lowering therapy (LLT) in patients with an acute coronary syndrome (ACS). AIM: To document the prevalence of lipid abnormalities and the achievement of lipid targets among patients surviving an ACS and in patients with stable coronary heart disease (CHD), using data from the DYSIS II study...
March 2017: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/28195517/systematic-underutilisation-of-secondary-preventive-drugs-in-patients-with-acute-coronary-syndrome-and-reduced-renal-function
#12
Masih Khedri, Karolina Szummer, Juan-Jesus Carrero, Tomas Jernberg, Marie Evans, Stefan H Jacobson, Jonas Spaak
Aims The high risk of recurrent events in patients with reduced renal function following an acute coronary syndrome (ACS) may in part be due to suboptimal secondary prevention. We aimed to describe the association between renal dysfunction and the prescription, initiation and persistent use of secondary prevention during the first year after a first ACS. Methods We identified all patients admitted to any Swedish coronary care unit for a first ACS between 2005 and 2010 ( n = 77,432). In 75,129 patients, creatinine levels were available in order to obtain the estimated glomerular filtration rate (eGFR)...
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28190615/effectiveness-of-a-combination-of-ezetimibe-and-statins-in-patients-with-acute-coronary-syndrome-and-multiple-comorbidities-a-6-year-population-based-cohort-study
#13
Fe-Lin Lin Wu, Jui Wang, Wei Ho, Chia-Hung Chou, Yi-Jung Wu, Dan-Wei Choo, Yu-Wen Wang, Po-Yu Chen, Kuo-Liong Chien, Zhen-Fang Lin
BACKGROUND: The clinical benefits of a combination of statins and ezetimibe in patients with acute coronary syndrome (ACS) were observed in a clinical trial. However, little is known regarding the effectiveness of using statins with or without ezetimibe in patients with ACS and multiple comorbidities in real-world clinical practice. METHODS: This is a nationwide population-based cohort study using Taiwan National Health Insurance Research Database. A total of 212,110 patients with ACS who had been discharged after their first ACS events between 2006 and 2010 were enrolled...
April 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28190386/high-density-lipoprotein-and-low-density-lipoprotein-therapeutic-approaches-in-acute-coronary-syndromes
#14
Emmanuel Androulakis, Effimia Zacharia, Nikolaos Papageorgiou, Eirini Lioudaki, Dimitris Bertsias, Marietta Charakida, Gerasimos Siasos, Dimitris Tousoulis
Low-density lipoprotein cholesterol (LDL), and especially its oxidized form, renders the atherosclerotic plaque vulnerable to rupture in acute coronary syndromes (ACS). On the other hand, high-density lipoprotein (HDL) is considered an anti-atherogenic molecule. The more recent HDL-targeted drugs may prove to be superior to those used before. Indeed, delipidated HDL and HDL mimetics are efficient in increasing HDL levels, while the apoA-I upregulation with RVX-208 appears to offer a clinical benefit which is beyond the HDL related effects...
February 9, 2017: Current Cardiology Reviews
https://www.readbyqxmd.com/read/28185473/statins-for-secondary-prevention-clinical-use-in-patients-with-acute-coronary-syndrome-in-wales
#15
Majd B Protty, Arron Lacey, Jamie Hayes, Phillip Freeman
AIM: Statins have a proven role for the secondary prevention of cardiovascular disease. Despite this, typical patient use in real life is variable. Our aim was to investigate the typical clinical use, including adherence, for statins in a sample population in South Wales (UK). METHODS: We identified 2248 patients admitted to hospitals in South Wales with acute coronary syndrome using a retrospective 3-year-long longitudinal study. We performed data linkage using the Secure Anonymized Information Linkage databank...
March 2017: Future Cardiology
https://www.readbyqxmd.com/read/28125968/the-ratio-of-serum-n-3-to-n-6-polyunsaturated-fatty-acids-is-associated-with-diabetes-mellitus-in-patients-with-prior-myocardial-infarction-a-multicenter-cross-sectional-study
#16
Masao Takahashi, Jiro Ando, Kazunori Shimada, Yuji Nishizaki, Shigemasa Tani, Takayuki Ogawa, Masato Yamamoto, Ken Nagao, Atsushi Hirayama, Michihiro Yoshimura, Hiroyuki Daida, Ryozo Nagai, Issei Komuro
BACKGROUND: In prior myocardial infarction (PMI) patients, diabetes mellitus (DM), dyslipidemia, and hypertension increase the risk of secondary cardiovascular events. Although a decreased ratio of serum eicosapentaenoic acid (EPA) to arachidonic acid (AA; EPA/AA) has been shown to significantly correlate with the onset of acute coronary syndrome, the associations between polyunsaturated fatty acid (PUFA) levels and coronary risk factors in PMI patients have not been evaluated thoroughly...
January 26, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28124399/comparative-effectiveness-of-recommended-versus-less-intensive-drug-combinations-in-secondary-prevention-of-acute-coronary-syndrome
#17
Julien Bezin, Rolf H H Groenwold, M Sanni Ali, Régis Lassalle, Philip Robinson, Anthonius de Boer, Nicholas Moore, Olaf H Klungel, Antoine Pariente
PURPOSE: The secondary prevention treatment for acute coronary syndrome (ACS) is based on the combined use of drugs from four therapeutic classes (beta-blockers, antiplatelet agents, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). The objective of this study was to compare the long-term effectiveness of the recommended therapeutic combination with those of incomplete combinations in secondary prevention of ACS. METHODS: This cohort study used data from a representative sample of the French national healthcare insurance system database...
January 26, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28104770/decline-in-cardiovascular-mortality-possible-causes-and-implications
#18
REVIEW
George A Mensah, Gina S Wei, Paul D Sorlie, Lawrence J Fine, Yves Rosenberg, Peter G Kaufmann, Michael E Mussolino, Lucy L Hsu, Ebyan Addou, Michael M Engelgau, David Gordon
If the control of infectious diseases was the public health success story of the first half of the 20th century, then the decline in mortality from coronary heart disease and stroke has been the success story of the century's past 4 decades. The early phase of this decline in coronary heart disease and stroke was unexpected and controversial when first reported in the mid-1970s, having followed 60 years of gradual increase as the US population aged. However, in 1978, the participants in a conference convened by the National Heart, Lung, and Blood Institute concluded that a significant recent downtick in coronary heart disease and stroke mortality rates had definitely occurred, at least in the US Since 1978, a sharp decline in mortality rates from coronary heart disease and stroke has become unmistakable throughout the industrialized world, with age-adjusted mortality rates having declined to about one third of their 1960s baseline by 2000...
January 20, 2017: Circulation Research
https://www.readbyqxmd.com/read/28099219/a-review-of-the-clinical-utility-of-intravascular-ultrasound-and-optical-coherence-tomography-in-the-assessment-and-treatment-of-coronary-artery-disease
#19
REVIEW
Stephen Daniel Matthews, William H Frishman
Coronary artery disease remains one of the leading causes of morbidity and mortality in the United States. As a medical society, we continue to search for ways to better treat coronary artery disease and prevent acute coronary syndrome (ACS). As it stands, only statins and antiplatelet agents have been proven to significantly reduce the occurrence of ACS. A histopathological understanding of the pathogenesis of ACS has provided insight into the importance of plaque morphology. Therefore, it has been proposed that increasing the ability to detect true vulnerable, "at-risk" lesions, would foster the use of percutaneous coronary intervention as a means for the prevention of ACS...
March 2017: Cardiology in Review
https://www.readbyqxmd.com/read/28097904/estimated-burden-of-cardiovascular-disease-and-value-based-price-range-for-evolocumab-in-a-high-risk-secondary-prevention-population-in-the-us-payer-context
#20
Peter P Toth, Mark Danese, Guillermo Villa, Yi Qian, Anne Beaubrun, Armando Lira, Jeroen P Jansen
AIM: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population. MATERIALS AND METHODS: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture complete CV burden including CV mortality. Patients on standard of care (SOC; high-intensity statins) in CPRD were selected based on eligibility criteria of FOURIER, a phase 3 CV outcomes trial of evolocumab, and categorized into four cohorts: high-risk prevalent atherosclerotic CVD (ASCVD) cohort (n = 1448), acute coronary syndrome (ACS) (n = 602), ischemic stroke (IS) (n = 151), and heart failure (HF) (n = 291) incident cohorts...
January 25, 2017: Journal of Medical Economics
keyword
keyword
45397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"